A Pap smear from a 28-year-old shows koilocytic cells with nuclear enlargement, hyperchromasia, irregular nuclear membranes, and perinuclear halos. HPV genotyping returns HPV 16 positive. Which molecular mechanism of HPV 16 E7 oncoprotein accounts for it being more carcinogenic than HPV 6 E7?

• A HPV 16 E7 activates telomerase via TERT promoter binding, providing limitless replicative potential not seen with HPV 6 E7
• B HPV 16 E7 directly activates CDK4/6, bypassing the need for Rb inactivation
• C HPV 16 E7 upregulates p16INK4A as a compensatory mechanism, driving paradoxical senescence more quickly than HPV 6
• D HPV 16 E7 has higher binding affinity for hypophosphorylated Rb protein compared to HPV 6 E7; stronger Rb degradation releases E2F transcription factors more completely, driving S-phase entry and overcoming the G1/S checkpoint more effectively ✓

Explanation

HPV E7 oncoprotein promotes cell cycle progression primarily by binding and inactivating the Rb tumor suppressor. Rb in its hypophosphorylated state sequesters E2F transcription factors; E7-mediated Rb degradation (via proteasomal pathway) liberates E2F to transactivate S-phase genes (CCNE1, DHFR, etc.). High-risk HPV 16 E7 contains zinc-binding and LXCXE motifs that confer 5–10-fold higher Rb-binding affinity compared to low-risk HPV 6 E7. This more complete Rb inactivation, combined with E6-mediated p53 degradation, allows permanent cell cycle deregulation and accumulation of additional mutations driving CIN-to-invasive carcinoma progression. p16INK4A is compensatorily upregulated as a biomarker of Rb inactivation, not a cause of E7 carcinogenicity.

Reference: Robbins & Cotran Pathologic Basis of Disease, 10th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.